Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes

Blood (2012) 120 (21): 1697.

https://doi.org/10.1182/blood.V120.21.1697.1697

Published: 2012

Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Blood (2012) 120 (21): 166.

https://doi.org/10.1182/blood.V120.21.166.166

Published: 2012

Journal Articles

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Nelson Spector, MD, PhD, Brian Leber, MD, Ricardo Pasquini, MD, PhD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Gabriel Etienne, MD, PhD, Agnès Guerci-Bresler, MD, Susan Branford, PhD, Das Purkayastha, LaTonya Collins, BSN, Tomasz Szczudlo, Francisco Cervantes, MD, PhD

Blood (2012) 120 (21): 694.

https://doi.org/10.1182/blood.V120.21.694.694

Published: 2012

Journal Articles

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

Jean-Claude Chomel, PharmD, PhD, Marie Laure Bonnet, Nathalie Sorel, PhD, Ivan Sloma, PharmD, PhD, Alexis Proust, Annelise Bennaceur-Griscelli, MD, PhD, Delphine Rea, MD, PhD, Madalina Uzunov, M.D., Laurence Legros, MD, PhD, Shanti Ame, MD, Anne Marfaing-Koka, Agnès Guerci, MD, Philippe Rousselot, MD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 3726.

https://doi.org/10.1182/blood.V120.21.3726.3726

Published: 2012

Journal Articles

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Blood (2012) 120 (21): 3770.

https://doi.org/10.1182/blood.V120.21.3770.3770

Published: 2012

Journal Articles

Phosphorylation of Spleen Tyrosine Kinase (Syk) Appears to Be Related to the Blast Phase of Chronic Myeloid Leukemia

Céline Bourgne, Alexandre Janel, Jacques Chassagne, PhD, Chantal Rapatel, Olivier Tournilhac, MD, PhD, Agnès Guerci, MD, Frédérique Lioret, Aurélie Briançon, Juliette Berger, Mahchid Bamdad, Nathalie Boiret-Dupré, Marc G Berger, MD, PhD

Blood (2012) 120 (21): 4425.

https://doi.org/10.1182/blood.V120.21.4425.4425

Published: 2012

Journal Articles

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Delphine Rea, MD, PhD, Philippe Rousselot, MD, PhD, François Guilhot, MD, Michel Tulliez, MD, Franck E. Nicolini, MD, PhD, Agnès Guerci-Bresler, MD, Laurence Legros, MD, PhD, Martine Gardembas, MD, Stephane Giraudier, MD, PhD, Gaelle Guillerm, MD, Francois-Xavier Mahon, MD, PhD

Blood (2012) 120 (21): 916.

https://doi.org/10.1182/blood.V120.21.916.916

Published: 2012

Journal Articles

Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk

Djamel Aggoune, Nathalie Sorel, PhD, Sanaa El Marsafy, MD, PhD, Marie Laure Bonnet, Denis Clay, Marie Claude Meunier, Karin Tarte, Olivier Herault, MD, PhD, Jorge Domenech, MD, PhD, Agnès Guerci, MD, Jean-Claude Chomel, PharmD, PhD, Ali G Turhan, M.D., PhD

Blood (2012) 120 (21): 908.

https://doi.org/10.1182/blood.V120.21.908.908

Published: 2012

Journal Articles

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD, Claude Preudhomme, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Franck E. Nicolini, MD, PhD, Francoise Rigal-Huget, MD, Hyacinthe Johnson-Ansah, MD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, Eric Jourdan, MD, Laurence Legros, MD, PhD, Francois Guilhot

Blood (2012) 120 (21): 168.

https://doi.org/10.1182/blood.V120.21.168.168

Published: 2012

Journal Articles

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Hyacinthe Johnson-Ansah, MD, Joelle Guilhot, Philippe Rousselot, MD, PhD, Rea Delphine, MD, PhD, Francoise Rigal-Huguet, MD, Franck E. Nicolini, MD, PhD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, PhD, Michele Schoenwald, MD, Eric Jourdan, Laurence Legros, Valérie Coiteux, MD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, Francois Guilhot

Blood (2011) 118 (21): 456.

https://doi.org/10.1182/blood.V118.21.456.456

Published: 2011

Journal Articles

Flow Cytometry Detection of Intra-Cellular Tyrosine Kinase Inhibitors (TKI) Showed Variable Uptake in CML CD34+ Cells

Céline Bourgne, Mahchid Bamdad, Alexandre Janel, Frédéric Libert, Agnès Guerci, MD, Marie-Claude Gagnieu, Chantal Rapatel, Pascale Pigeon, Sylvie Pereira, Eric Hermet, MD, Pascale Cony Makhoul, Atchroue Johnson-Ansah, Jean Yves Cahn, MD, Denis Guyotat, Sébastien Trouillier, Juliette Berger, Nathalie Boiret-Dupré, Marc G Berger, MD, PhD

Blood (2011) 118 (21): 2747.

https://doi.org/10.1182/blood.V118.21.2747.2747

Published: 2011

Journal Articles

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, Joelle Guilhot, Francois Guilhot, Françoise Huguet, MD, Franck E. Nicolini, MD, PhD, Laurence Legros, Aude Charbonnier, Agnès Guerci, MD, Bruno R. Varet, MD, Gabriel Etienne, MD, PhD, Josy Reiffers, MD, Philippe Rousselot, MD, PhD

Blood (2011) 118 (21): 603.

https://doi.org/10.1182/blood.V118.21.603.603

Published: 2011

Journal Articles

Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases

Blood (2010) 116 (21): 2171.

https://doi.org/10.1182/blood.V116.21.2171.2171

Published: 2010

Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Blood (2010) 116 (21): 1880.

https://doi.org/10.1182/blood.V116.21.1880.1880

Published: 2010

Journal Articles

High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL).

Ramzi Jeddi, Béchir Achour, Agnès Guerci-Bresler, Héla Ghédira, Hervé Dombret, Françoise Huguet, Patrice Chevallier, Norbert Vey, Stephane de Botton, Dominique Bordessoule, Beatrice U. Muller, Virginie Eclache, Claude Gardin, Balkis Meddeb, Lionel Adès, Pierre Fenaux, MD, PhD

Blood (2010) 116 (21): 1078.

https://doi.org/10.1182/blood.V116.21.1078.1078

Published: 2010

Journal Articles

Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.

Philippe Rousselot, MD, PhD, Stéphane Boucher, MD, PhD, Gabriel Etienne, MD, PhD, Franck E Nicolini, MD, PhD, Emmanuelle Chauzit, MD, Pascale Cony Makhoul, MD, Valérie Coiteux, MD, Agnès Guerci, MD, Martine Gardembas, MD, Laurence Legros, MD, Lydia Roy, MD, Caroline Dartigeas, MD, Maud Janvier, MD, Christian Berthou, MD, Lambert Busque, MD, FRCPC, Mathieu Molimard, MD, PhD, Joelle Guilhot, PhD, Luigina Mollica, MD, FRCPC, PhD, Francois-Xavier Mahon, MD, PhD

Blood (2010) 116 (21): 3432.

https://doi.org/10.1182/blood.V116.21.3432.3432

Published: 2010

Journal Articles

Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group

Blood (2010) 116 (21): 505.

https://doi.org/10.1182/blood.V116.21.505.505

Published: 2010

Journal Articles

Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials.

Gonzalo Ariel Ferini, PhD, MD, Emmanuel Raffoux, MD, Agnès Guerci, Arnaud Pigneux, MD, PhD, Françoise Huguet, Norbert Vey, Thierry Lamy, Beatrice Muller, Patrice Chevallier, Sylvie Castaigne, MD, Pascal Turlure, Augustin Ferrant, Norbert Ifrah, Stephane de Botton, Hervé Dombret, Lionel Ades, Pierre Fenaux, MD, PhD

Blood (2010) 116 (21): 1084.

https://doi.org/10.1182/blood.V116.21.1084.1084

Published: 2010

Journal Articles

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Norbert Gattermann, MD, Carlo Finelli, MD, Matteo Della Porta, MD, Pierre Fenaux, MD, PhD, Michael Stadler, MD, Agnès Guerci-Bresler, MD, Mathias Schmid, MD, Kerry Taylor, MD, Dominique Vassilieff, MD, Dany Habr, MD, Andrea Marcellari, MS, MT(ASCP), Bernard Roubert, PhD, Christian Rose, MD

Blood (2010) 116 (21): 2912.

https://doi.org/10.1182/blood.V116.21.2912.2912

Published: 2010

Journal Articles

Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Sophie Park, MD, PhD, Rosa Sapena, Dominique Vassilieff, Charikleia Kelaidi, Dominique Bordessoule, Aspasia Stamatoullas, Stéphane Cheze, Odile Beyne-Rauzy, Norbert Vey, MD, Christian Rose, Agnès Guerci, Shanti Ame, Gerard Tertian, Borhane Slama, MD, Pierre Fenaux, Francois Dreyfus

Blood (2010) 116 (21): 2916.

https://doi.org/10.1182/blood.V116.21.2916.2916

Published: 2010

NARROW

BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Evaluation of Leukemic Stem Cell Persistence in Chronic Myeloid Leukemia (CML) Patients in Complete Molecular Remission Induced by First Line TKI Therapies

Pharmacologic Monitoring of Dasatinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP-CML) Identifies Patients At Higher Risk of Pleural Effusion: A Sub-Analysis of the OPTIM-Dasatinib Trial

Phosphorylation of Spleen Tyrosine Kinase (Syk) Appears to Be Related to the Blast Phase of Chronic Myeloid Leukemia

Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts

Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Flow Cytometry Detection of Intra-Cellular Tyrosine Kinase Inhibitors (TKI) Showed Variable Uptake in CML CD34+ Cells

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM Study

Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

High Body Mass Index (BMI) as a Predictor of Differentiation Syndrome (DS) In Acute Promyelocytic Leukemia (APL).

Pharmacokinetics of Dasatinib as a First Line Therapy In Newly Diagnosed CML Patients (OPTIM dasatinib trial): Correlation with Safety and Response.

Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group

Central Nervous System (CNS) at First Relapse In APL. A Report on 2 Multicenter Trials.

Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria

Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only